Finance

Beta
Lists
1801:HKG
Innovent Biologics Inc
HK$76.60
+0.26%
(+0.20) 1D
Jun 5, 4:09:10 PM GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 1801...
Open
HK$77.35
High
HK$79.80
Low
HK$76.10
Mkt. cap
132.46B
Avg. vol.
13.42M
Volume
15.10M
P/E ratio
141.46
52-wk high
HK$109.10
52-wk low
HK$70.55
EPS
HK$0.54
No. of employees
8K
Open
HK$77.35
High
HK$79.80
Low
HK$76.10
Mkt. cap
132.46B
Avg. vol.
13.42M
Volume
15.10M
P/E ratio
141.46
52-wk high
HK$109.10
52-wk low
HK$70.55
EPS
HK$0.54
No. of employees
8K
Analyst outlook
Analyst Ratings
Based on 15 analysts giving stock ratings to 1801 in the past 3 months
Strong Buy
Buy
15
Hold
0
Sell
0
12 month forecast
Based on 15 Wall Street analysts offering 12 month price targets for 1801 in the last 3 months.
Highest
Current HK$76.60
HK$147.70 (+92.82%)
Average
HK$120.49 (+57.30%)
Lowest
HK$105.00 (+37.08%)
News stories
From sources across the web
Profile
Innovent Biologics, Inc. is a publicly listed Chinese biopharmaceutical company that is headquartered in Suzhou, Jiangsu. Wikipedia
About Innovent Biologics Inc
CEOMichael Yu
Employees7.5K
FoundedNov 28, 2011
Headquarters-
SectorBiotechnology
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
2.98B
2.98B
3.54B
3.54B
Cost of goods sold
676.78M
676.78M
845.12M
845.12M
Cost of revenue
676.78M
676.78M
845.12M
845.12M
Research and development expenses
504.40M
504.40M
807.71M
807.71M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.41B
1.41B
1.91B
1.91B
Operating expense
1.91B
1.91B
2.72B
2.72B
Total operating expenses
2.59B
2.59B
3.56B
3.56B
Operating income
386.78M
386.78M
-19.96M
-19.96M
Other non operating income
13.49M
13.49M
45.19M
45.19M
EBT including unusual items
448.56M
448.56M
-29.10M
-29.10M
EBT excluding unusual items
434.82M
434.82M
-1.59M
-1.59M
Income tax expense
31.40M
31.40M
-18.72M
-18.72M
Effective tax rate
7.00%
7.00%
64.33%
64.33%
Other operating expenses
-
-
-
-
Net income
417.16M
417.16M
-10.38M
-10.38M
Net profit margin
14.01%
14.01%
-0.29%
-0.29%
Earnings per share
-
-
-
-
Interest and investment income
95.19M
95.19M
124.16M
124.16M
Interest expense
-30.63M
-30.63M
-9.17M
-9.17M
Net interest expenses
64.55M
64.55M
114.99M
114.99M
Depreciation and amortization charges
-
-
-
-
EBITDA
514.79M
514.79M
140.29M
140.29M
Gain or loss from assets sale
355.50K
355.50K
-71.00K
-71.00K
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more